ACNP 1 DM- Questions and Answers
First line treatment in DM type 2 Correct Ans-Metformin, no hypo and helps weight loss
Metformin contraindicated in Correct Ans-Renal failure, hold with radioactive dye
Second generation sulfonylureas Correct Ans-Glipizide, glyburide, glimepiride
Sulfonyleureas can causes Correct Ans-hypoglycemia, wt gain
the mechanism of action of sulfonylureas is as:
a. an antagonist of insulin receptor site activity
b. a product that enhances insulin release
c. a facilitator of renal glucose excretion
d. an agent that can reduce hepatic glucose production Correct Ans-b. a product that enhances
insulin release
hemoglobin A1c best provides information on glucose control over the past:
a. 1 - 29 days
b. 21 - 47 days
c. 48- 63 days
d. 64 to 90 days Correct Ans-d. 64 to 90 days
, Acarbose & Miglitol disadvantage Correct Ans-flatulance, not monotherapy
Piogitazone and Rosiglitazone Correct Ans-thiazolidinediones; Black box warning for HF,
measure ALT!
Meglintinides help with Correct Ans-post prandial Hyperglycemia
exenatide use can lead to Correct Ans-pancreatitis, gastroparesis, thyroid CA. GLP-1
mechanism of action of the DPP-4 Correct Ans-(gliptins) a drug that increases levels of
incretin, increasing synthesis and release of insulin from pancreatic beta cells
mechanism of action of exenatide Correct Ans-drug that stimulates insulin production in
response to increase in plasma glucose, slows gastric emptying
Somogyi Effect Correct Ans-Nocturnal hypoglycemia which rebounds to elevated glucose
Dawn phenomenon Correct Ans-tissue desensitized to insulin nocturnally. Progressively
elevated insulin throughout the night
DKA occurs in Correct Ans-Type 1 possibly from infection
First line treatment in DM type 2 Correct Ans-Metformin, no hypo and helps weight loss
Metformin contraindicated in Correct Ans-Renal failure, hold with radioactive dye
Second generation sulfonylureas Correct Ans-Glipizide, glyburide, glimepiride
Sulfonyleureas can causes Correct Ans-hypoglycemia, wt gain
the mechanism of action of sulfonylureas is as:
a. an antagonist of insulin receptor site activity
b. a product that enhances insulin release
c. a facilitator of renal glucose excretion
d. an agent that can reduce hepatic glucose production Correct Ans-b. a product that enhances
insulin release
hemoglobin A1c best provides information on glucose control over the past:
a. 1 - 29 days
b. 21 - 47 days
c. 48- 63 days
d. 64 to 90 days Correct Ans-d. 64 to 90 days
, Acarbose & Miglitol disadvantage Correct Ans-flatulance, not monotherapy
Piogitazone and Rosiglitazone Correct Ans-thiazolidinediones; Black box warning for HF,
measure ALT!
Meglintinides help with Correct Ans-post prandial Hyperglycemia
exenatide use can lead to Correct Ans-pancreatitis, gastroparesis, thyroid CA. GLP-1
mechanism of action of the DPP-4 Correct Ans-(gliptins) a drug that increases levels of
incretin, increasing synthesis and release of insulin from pancreatic beta cells
mechanism of action of exenatide Correct Ans-drug that stimulates insulin production in
response to increase in plasma glucose, slows gastric emptying
Somogyi Effect Correct Ans-Nocturnal hypoglycemia which rebounds to elevated glucose
Dawn phenomenon Correct Ans-tissue desensitized to insulin nocturnally. Progressively
elevated insulin throughout the night
DKA occurs in Correct Ans-Type 1 possibly from infection
